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a b s t r a c t
Increased rates of brain atrophy measured from serial magnetic resonance imaging precede symptom
onset in Alzheimer’s disease and may be useful outcome measures for prodromal clinical trials. Appro-
priate trial design requires a detailed understanding of the relationships between b-amyloid load and
accumulation, and rate of brain change at this stage of the disease. Fifty-two healthy individuals (72.3 
6.9 years) from Australian Imaging, Biomarkers and Lifestyle Study of Aging had serial (0, 18 m, 36 m)
magnetic resonance imaging, (0,18m) Pittsburgh compound B positron emission tomography, and clinical
assessments. We calculated rates of whole brain and hippocampal atrophy, ventricular enlargement,
amyloid accumulation, and cognitive decline. Over 3 years, rates of whole brain atrophy (p < 0.001), left
and right hippocampal atrophy (p ¼ 0.001, p ¼ 0.023), and ventricular expansion (p < 0.001) were asso-
ciatedwith baseline b-amyloid load.Whole brain atrophy rateswere also independently associatedwith b-
amyloid accumulation over the ﬁrst 18 months (p ¼ 0.003). Acceleration of left hippocampal atrophy rate
was associatedwith baseline b-amyloid load across the cohort (p< 0.02).We provide evidence that rates of
atrophy are associated with both baseline b-amyloid load and accumulation, and that there is presymp-
tomatic, amyloid-mediated acceleration of hippocampal atrophy. Clinical trials using rate of hippocampal
atrophy as an outcome measure should not assume linear decline in the presymptomatic phase.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Beta-amyloid (Ab) deposition is one of the key hallmarks of
Alzheimer’s disease (Braak and Braak, 1997) and, according to the
amyloid cascade hypothesis (Hardy and Selkoe, 2002), is a prime
mover in the sequence of events leading to neurodegeneration and
cognitive decline. The emergence of cerebrospinal ﬂuid (CSF)
measures of Ab (Blennow and Hampel, 2003; Palmert et al., 1990)
and positron emission tomography (PET) using ligands that bind to
ﬁbrillar amyloid deposits (Clark et al., 2011; Klunk et al., 2004)
allow for Ab deposition to be quantiﬁed in life. This in turn has led
not only to the development of new, and potentially more speciﬁc
criteria for the diagnosis of Alzheimer’s disease incorporating
biomarker evidence for Ab deposition (Dubois et al., 2007, 2014;
Jack et al., 2011a; McKhann et al., 2011), but also to fundamental
changes in how we conceptualize Alzheimer’s disease pathogen-
esis. The ﬁnding that approximately one-third of apparently
healthy people in their 70s have signiﬁcant levels of brain Ab as
determined using CSF (Shaw et al., 2009) or PET (Bourgeat et al.,
2010; Jack et al., 2008a; Pike et al., 2007; Rowe et al., 2010) com-
plements similar ﬁndings from autopsy studies (Knopman et al.,
2003; Price and Morris, 1999), and has led to the deﬁnition of
asymptomatic amyloidosis as a potentially presymptomatic
Alzheimer’s disease state (Morris et al., 1996, 2005; Sperling et al.,
2009, Dubois et al., 2010), now formalized in research diagnostic
criteria (Sperling et al., 2011a).
Biomarker studies of both familial Alzheimer’s disease
(Bateman et al., 2012) and aging, mild cognitive impairment
(MCI), and sporadic Alzheimer’s disease (Jack et al., 2013;
Villemagne et al., 2013) have provided evidence to suggest that,
at least in vulnerable individuals, amyloid accumulation may
lead to a cascade of events including network breakdown
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(measured using task free functional magnetic resonance imaging
[MRI]), neuronal destruction (reﬂected by elevation of CSF tau),
and increased rates of brain atrophy (quantiﬁed using serial MRI)
in vulnerable regions. Importantly, all these events are thought to
precede the development of cognitive decline and symptoms by a
decade or more in the case of Ab accumulation, and several years
in the case of excess atrophy rates, opening a potential window
for secondary prevention studies aiming to prevent or delay the
time to the development of cognitive impairment (Bateman et al.,
2011; Desikan et al., 2012; Sperling et al., 2011b, 2014). Formalized
and revised in a series of highly inﬂuential articles (Jack et al.,
2010, 2011b, 2012, 2013), current hypotheses predict not only
the sequence of changes occurring during the prodromal phase of
Alzheimer’s disease (Young et al., 2014) but also the trajectory of
biomarker changes in this sequence, suggesting that the rate at
which each biomarker becomes abnormal occurs in a sigmoidal
fashion, that is, showing initial rapid acceleration followed by a
period of linear increase, before decelerating toward a steady
state as the biomarker in question becomes abnormal (Caroli and
Frisoni, 2010; Sabuncu et al., 2011). If, as predicted, amyloid
accumulation precedes increased rates of atrophy, it would be
expected that rates of atrophy in regions sensitive to Alzheimer’s
disease pathology, for example, the medial temporal lobe (Braak
and Braak, 1997) would be higher in amyloid-positive cogni-
tively normal individuals than in those without Ab deposition;
and if biomarker changes do follow a sigmoidal trajectory, that
acceleration in rates of atrophy in vulnerable regions would relate
to amyloid deposition. If indeed there were acceleration in rates
of atrophy in prodromal Alzheimer’s disease (AD), this would
have implications for clinical trials in asymptomatic amyloidosis.
Such trials typically include rate of hippocampal atrophy as an
outcome measure, with the premise that a disease-modifying
therapy would slow rates of atrophy toward that of controls,
and are often predicated on rates of atrophy following a linear
trajectory.
In this study, using 3 time-point data from the Australian Im-
aging, Biomarkers and Lifestyle Study of Aging (AIBL) study, we
aimed to investigate the dynamics of neurodegeneration in rela-
tionship to amyloid load and accumulation in asymptomatic
elderly subjects. In particular, we aimed to determine (1) the
relationship between absolute measures of amyloid load and rates
of amyloid accumulation with rates of atrophy; (2) if, as predicted
by current hypothetical models, there is acceleration of regional
rates of atrophy in amyloid-positive individuals; and (3) if so, the
impact that this acceleration might have on the design of trials in
asymptomatic amyloidosis using rates of atrophy as outcome
measures.
2. Methods
2.1. Subjects
We downloaded data from the AIBL study available on the
Laboratory of Neuro Imaging database (http://www.loni.usc.edu/).
We included subjects designated as healthy controls at baseline
who had PiB 11C PET scans at baseline and 18 months and 3T MRI
volumetric scans at baseline, 18 months and 3 years. Details of the
AIBLmethodology have previously been reported (Ellis et al., 2009).
Brieﬂy, healthy controls 60 years old were recruited from the
community, w50% having subjective memory complaints
(subjective cognitive impairment, SCI), and w50% being APOE ε4
carriers. All subjects underwent standardized clinical and neuro-
psychological examinations, including the Mini-Mental State
Examination (MMSE), clinical dementia rating (CDR) scale, and
tests of immediate and delayed logical memory. Subjects were
assessed for the presence or absence of subjective cognitive
impairment and underwent apolipoprotein E (APOE) genotyping.
Austin Health Human Research Ethics Committee approved the
study and subjects provided written informed consent.
2.2. Image acquisition
PiB-PET scanswere acquired using an Allegro PETcamera (Phillips
Medical Systems, the Netherlands). A transmission scan was
performed for attenuation correction. Participants received 370MBq
11C-PiB over 1 minute, and a 20-minute acquisition (6  5-minute
frames) in 3D-mode was performed beginning 50 minutes after in-
jection. PET images were reconstructed using a 3D row-action
maximum-likelihood algorithm. Summed images from the
50e70 minute time-frames were used in this study. Sagittal
T1-weighted MRI brain scans were acquired using a 3D magnetiza-
tion prepared rapid gradient echo sequence on a Siemens TrioTim 3T
scanner, with 1 1 mm in-plane resolution; 1.2 mm slice thickness;
repetition time/echo time/inversion time ¼ 2300 ms/2.98 ms/
900 ms; ﬂip angle ¼ 9; ﬁeld-of-view ¼ 240  256; and 160 slices.
2.3. Image analysis
2.3.1. MRI volumes and atrophy rates
Images were corrected for intensity inhomogeneity using the N3
algorithm (Boyes et al., 2008) and whole brain segmentations pro-
duced at each time point using BrainMAPS (Leung et al., 2011). After
9-degrees-of-freedom registration of the follow-up to baseline
scans and differential bias correction (Lewis and Fox, 2004), hip-
pocampal segmentations were produced at each time point using
HippoMAPS (Leung et al., 2010a). Each segmentation underwent a
visual quality control process, with minimal manual editing where
necessary. Ventricular volumeswere delineated semi-automatically
using the MIDAS software package (Evans et al., 2010). Volume
change over time (mL) was calculated for ventricles (Schott et al.,
2010a), hippocampi (Leung et al., 2010a), and whole brain (Leung
et al., 2010b) using the boundary shift integral. Baseline total
intracranial volume (TIV) was estimated using the FreeSurfer
(http://surfer.nmr.mgh.harvard.edu/) image analysis suite v4.5.0
(Buckner et al., 2004).
2.3.2. Amyloid PET processing
MRI and PET images were processed as previously described
(Andrews et al., 2013) to calculate mean neocortical PiB uptake.
Brieﬂy, the MRI were segmented into tissue classes using NiftySeg
(Cardoso et al., 2011) and into regions of interest by registration
with NiftyReg (Modat et al., 2010) to the Hammers 30-subject atlas
set (Hammers et al., 2003) followed by label fusionwithMultiSTEPS
(Cardoso et al., 2013). The gray matter segmentation was combined
with a subset of regions of interest (frontal, temporal, parietal and
occipital lobes plus insula and cingulate cortex) to create a
neocortical mask. The PET image was rigidly registered to the cor-
respondingMRI and normalized by themean cerebellar graymatter
uptake to produce standardized uptake value ratios (SUVRs). Mean
neocortical SUVR was then calculated in PET space as the robust
fractional-volume-weighted mean under the neocortical mask.
2.4. Statistical methods
For the purposes of understanding the relationship between
amyloid load, amyloid accumulation, atrophy rates, and cognitive
scores, analyses were performed on the whole cohort. Although
likely to have lower statistical power than analyses treating amyloid
load as continuous, for the purposes of considering the design of
future clinical trials, we additionally dichotomized individuals as
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amyloid positive and/or negative using a baseline SUVR of 1.4 as
previously described (Andrews et al., 2013).
2.4.1. Cross-sectional analyses
We used unpaired t tests (allowing for unequal variances) to
compare mean ages between the amyloid-positive and -negative
groups. Fisher’s exact test was used to compare APOE ε4-positive
proportions between these groups. Paired t tests were used to test
hippocampal asymmetry within these groups, with an unpaired t
test used to compare the extent of the asymmetry between the
groups. Baseline brain volumes were compared between groups
using generalized least squares regression models to adjust for po-
tential effects of age, gender, and TIV. Generalized least squares
models were used to allow the residual variance to differ in the 2
groups. An analogous model, but adjusting for age, gender, and
(categorized) years of education was used to compare baseline
cognitive scores.
2.4.2. Analysis of longitudinal change
The repeated longitudinal measures of cognition were analyzed
using generalized least squares models to allow for potential differ-
ences in variance between groups and between time points and in
the correlations between the various pairs of repeated measures.
Models assumed unstructured covariance matrices for the repeated
measures at the 3 time points with the variances and correlations
betweenpairs ofmeasurements separately estimated in theamyloid-
positive and -negative groups.Models assumed linear rates of change
in each group with covariates such as age, gender, and education
allowed to inﬂuence both absolute levels and rates of change.
The repeated longitudinal measures of change in brain volumes
were also analyzed using generalized least squares models. Models
assumed unstructured covariance matrices for the 2 measures of
change with the variances and correlations between pairs of mea-
surements separately estimated in the amyloid-positive and
-negative groups. Models assumed linear rates of change in each
group with covariates such as age, gender, and TIV allowed to in-
ﬂuence rates of change. Furthermore, models assessed acceleration
by incorporating quadratic effects of time andwith the extent of the
acceleration allowed to depend on covariates. One set of models
treated amyloid load as a continuous variable, whilst a second set
dichotomized the subjects into 2 groups as mentioned previously.
2.4.3. Sample size estimates for trials
To explore the inﬂuence of thedynamics of longitudinal change in
atrophy rates on clinical trial design, we used data from amyloid-
positive individuals to estimate required sample sizes for clinical
trials thatprovide80%power, 5%type-1error, todetecta25%absolute
reduction in whole brain, ventricular, and hippocampal change over
each 18-month period, and over 36 months. Bias-corrected and
accelerated 95% bootstrap (100,000 samples) conﬁdence intervals
(Efron and Tibshirani, 1994) were found for required sample size
estimates and for ratios of such estimates (analyzed on a logarithmic
scale). Analyses were performed in Stata13 (Stata Corp, TX).
3. Results
3.1. Demographics and baseline characteristics
Complete data for 53 individuals were available. One individual
who had progressed to non-AD dementia was excluded. Twenty-
three of 52 (44%) were male, mean (SD) age was 72.3 
6.9 years, baseline MMSE was 29.2  1.2, 15/52 (29%) were APOE ε4
positive, 12/52 (23%) had SCI, 49/52 had a CDR ¼ 0, the remaining 3
had a CDR of 0.5, and 13/52 (25%) were amyloid positive at a cutoff
SUVR ¼ 1.4. Amyloid-positive individuals were slightly older but not
signiﬁcantly so (74.3 vs. 71.6; p ¼ 0.17) but were more likely to be
APOE ε4 positive (61.5% vs. 18.0%; p ¼ 0.005). Fifty were classiﬁed as
“normal control” at all 3 time points; one individual was reclassiﬁed
as “MCI” at 18 months and “Alzheimer’s disease” at 36 months,
another as “Alzheimer’s disease” at both 18 months and 36 months.
Cognitive scores, amyloid load (global cortical SUVR), and global
and regional volumes at baseline are shown in Table 1 for thewhole
cohort, and for amyloid-positive and -negative groups. In the
cohort, as a whole, there was statistically signiﬁcant (right > left)
hippocampal asymmetry (p < 0.0001), with no evidence (p ¼ 0.4)
that the extent of the asymmetry differed between the amyloid-
positive and -negative individuals. There was no evidence that
the cognitive scores differed between the amyloid-positive and
-negative groups. Although unadjusted mean brain volumes were
similar in the amyloid-positive and -negative groups, after adjust-
ment for age, gender, and TIVwhole brain volumes were on average
30 mL (95% CI 2e57 mL, p ¼ 0.037) smaller in the amyloid-positive
group compared with the negative group, this largely being a
consequence of the fact that the mean TIV in the amyloid-positive
group was somewhat larger than that in the negative group. Ven-
tricular and hippocampal volumes were similar in the 2 groups.
3.2. Longitudinal changes over 36 months
3.2.1. Changes in cognition and amyloid load
Table 2 shows the mean and standard deviation of rates of
change in cognitive outcomes and in SUVR in the amyloid-positive
Table 1
Cognitive scores, SUVR, and brain volumes at baseline
All individuals
(n ¼ 52)
Amyloid positive
(SUVR > 1.4; n ¼ 13)
Amyloid negative
(SUVR < 1.4; n ¼ 39)
Comparison amyloid
positive versus negative
Mean SD Mean SD Mean SD Adjusteda mean
difference (95% CI)
SUVR 1.33 0.32 1.82 0.29 1.17 0.06 d
MMSE 29.2 1.2 29.2 1.2 29.1 1.2 0.4 (0.2, 1.1)
Logical memory immediate recall 13.1 4.0 12.2 3.8 13.4 4.0 1.1 (3.6, 1.4)
Logical memory delayed recall 11.9 (2) 4.1 11.8 (1) 3.7 11.9 (1) 4.2 0.2 (2.5, 2.9)
Total intracranial volume (mL) 1509 149 1552 148 1494 149 d
Brain volume (mL) 1088 94 1086 91 1089 97 L30 (L57,L2)
Ventricular volume (mL) 35.0 19.6 38.0 22.9 34.0 18.6 1.1 (13.2, 10.9)
Left hippocampal volume (mL) 2.62 0.37 2.65 0.45 2.61 0.35 0.07 (0.19, 0.33)
Right hippocampal volume (mL) 2.74 0.37 2.74 0.46 2.73 0.34 0.00 (0.27, 0.26)
Numbers in brackets are numbers of missing observations.
Statistically signiﬁcant (p < 0.05) results are shown in bold.
Key: MMSE, Mini-Mental State Examination; SUVR, standardized uptake value ratio.
a Comparisons made after adjustment for age, gender and total intracranial volume (imaging outcomes) and age, gender, and education (others).
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and -negative groups in the 2 follow-up periods. On average, over
the 36month period, MMSE scores declined in the amyloid-positive
group with a mean rate of change of 0.4/y (95% CI 0.1e0.7 mL/y,
p ¼ 0.015). Directionally similar changes were seen for the other 2
cognitive measures with that for delayed logical memory being of
borderline statistical signiﬁcance (p ¼ 0.055). In contrast, there was
little or no mean change in the amyloid-negative group, with both
themeanMMSE rate of change (p¼ 0.021) and the rate of change in
the delayed logical memory test (p ¼ 0.029) differing signiﬁcantly
from the analogous rates in the amyloid-positive group after
adjusting for age, gender, and years of education.
The mean rate of change in SUVR between baseline and
18 months was 0.01 per year (95% CI 0.001e0.02, p ¼ 0.026) across
the whole cohort. The mean rate in those who were amyloid
positive at baseline was around 3 times that in those who were
amyloid negative, although this difference was not statistically
signiﬁcant (p ¼ 0.13).
3.2.2. Relating rates of volume change over 36 months to amyloid
load
Fig. 1 plots the subject speciﬁc annualized rates of change in
whole brain, ventricular, and left and right hippocampal volumes
against baseline amyloid load in the 2 time periods. From the
repeated measures generalized least squares regression models,
higher baseline amyloid load was signiﬁcantly associated with
increased rates of whole brain atrophy (p < 0.001), ventricular
expansion (p < 0.001), and left (p ¼ 0.001) and right hippocampal
atrophy rates (p ¼ 0.023) after adjustment for age, gender, and TIV.
These associations were little altered and remained statistically
signiﬁcant (all p < 0.01) after additionally adjusting simultaneously
for years of education, MMSE, CDR, SCI, and APOE ε4 status.
Extending the regression models described previously to simul-
taneously investigate the effects of baseline amyloid load and rate of
amyloid accumulation on rates (adjusting for effects of age, gender,
and TIV) provided some evidence of an independent effect of amyloid
accumulation. Speciﬁcally, for whole brain atrophy rate, there was
statistically signiﬁcant evidence (p ¼ 0.003) that an increased rate of
accumulation was associated with increased atrophy. For ventricular
expansion, and both left and right hippocampal atrophy rates,
directionally consistent resultswere seenwith borderline statistically
signiﬁcant p-values (between 0.063 and 0.101).
3.2.3. Comparing volume changes in amyloid-positive and -negative
groups
Table 2 shows the mean and standard deviation rates of volume
change in the amyloid-positive and -negative groups together with
estimated mean rates of change and 95% CI. All mean rates of at-
rophy were markedly higher in the amyloid-positive group, with
rates of whole brain atrophy and ventricular expansion approxi-
mately double, and hippocampal atrophy measures more than
double those in the amyloid-negative group.
3.3. Longitudinal changes over 0e18 and 18e36 month intervals
3.3.1. Acceleration in atrophy rates
Table 2 also shows estimates of acceleration in atrophy rates
estimated from linear mixed models that allowed the rate of atro-
phy to change with time. In the amyloid-positive group, rates of left
and right hippocampal atrophy in the second 18-month period
were more than double those seen in the ﬁrst, this acceleration
being statistically signiﬁcant (p < 0.05) for both structures. Results
for rates of whole brain atrophy and ventricular expansion were
also suggestive of acceleration, although these effects were not
statistically signiﬁcant. In the amyloid-negative group, both hip-
pocampal atrophy rates were somewhat higher in the second 18-
month period than the ﬁrst although the size of the difference
was markedly smaller than that for the amyloid-positive group and
not statistically signiﬁcant. Comparisons of hippocampal accelera-
tion between the 2 groups (adjusting for age, gender, and TIV) did
not give statistically signiﬁcant results, although results for the left
hippocampus were borderline statistically signiﬁcant (p ¼ 0.058).
Furthermore, an analysis that treated amyloid load as a continuous
variable did provide statistically signiﬁcant evidence that the ac-
celeration in left hippocampal atrophy rate was associated with
amyloid load (p ¼ 0.018).
Table 2
Comparison of rates of change over each time period for selected variables
0e18 m,
mean  SD
18e36 m, mean  SD Mean ratea
(95% conﬁdence interval)
Acceleration/yrb
(95% conﬁdence interval)
Amyloid positive (SUVR > 1.4; n ¼ 13)
Consecutive scan interval (d) 545  89 579  64 d d
Increase in SUVR (SUVR/yr) 0.024  0.053 d d d
Change in MMSE/y 0.9  0.9 0.1  0.8 L0.4 (L0.7, L0.1) d
Change in logical memory immediate/y 0.2  2.4 0.7  2.9 0.4 (1.3, 0.5)
Change in logical memory delayed/y 0.0  3.2 0.5  2.6 0.6 (1.1, 0.0)
Brain atrophy (mL/y) 5.6  5.2 9.1  5.9 7.1 (5.4, 8.8) 2.7 (0.6, 5.9)
Ventricular expansion (mL/y) 1.8  1.4 2.4  1.9 2.0 (1.2, 2.8) 0.4 (0.1, 0.8)
Left hippocampal atrophy (mL/y) 17  28 48  39 27 (14, 41) 24 (8, 40)
Right hippocampal atrophy (mL/y) 18  24 37  38 18 (4, 31) 13 (0, 25)
Amyloid negative (SUVR < 1.4; n ¼ 39)
Consecutive scan interval (d) 551  97 592  70 d d
Increase in SUVR (SUVR/y) 0.007  0.025 d d d
Change in MMSE/y 0.1  0.9 0.0  0.8 0.0 (0.2, 0.1) d
Change in logical memory immediate/y 0.2  2.5 0.1  2.0 0.0 (0.4, 0.4) d
Change in logical memory delayed/yr 0.6  2.9 0.1  1.7 0.2 (0.2, 0.5) d
Brain atrophy (mL/y) 4.3  5.3 3.1  3.9 3.6 (2.7, 4.5) 0.3 (1.7, 1.0)
Ventricular expansion (mL/y) 1.0  0.9 1.2  1.1 1.1 (0.8, 1.3) 0.1 (0.1, 0.3)
Left hippocampal atrophy (mL/y) 9  24 15  22 12 (8, 17) 6 (1, 12)
Right hippocampal atrophy (mL/y) 7  31 10  26 8 (3, 13) 6 (2, 14)
Key: MMSE, Mini-Mental State Examination; SUVR, standardized uptake value ratio.
a Derived from a generalized least squares regression model (see statistical methods) where the rate of change is assumed constant over the 2 periods. Statistically sig-
niﬁcant (p < 0.05) results (where the 95% conﬁdence interval does not span 0) are shown in bold.
b Derived from a generalized least squares regressionmodel (see statistical methods) where the rate of change over the 2 periods is assumed to change at a constant rate. The
acceleration is the change in rate over 1 year. Statistically signiﬁcant (p < 0.05) results are shown in bold.
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3.3.2. Sample size estimates
Recruiting amyloid-positive subjects to power a 3-year treat-
ment trial to detect 25% per year absolute slowing of cerebral at-
rophy rates requires 44 (95% CI 20e96) subjects per arm using
whole brain atrophy,139 (84e232) using ventricular expansion,161
(89e359) using left hippocampal atrophy rates, and 271 (129e788)
using right hippocampal atrophy rates. Comparing sample size es-
timates across the 2 available 18 month time periods, numbers
estimated to detect a 25% absolute reduction in rate of ventricular
expansion were very similar, although with wide 95%
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Fig. 1. Atrophy rates by period and region. In panels showing rates in period 2 closed triangles (red closed circles in the web version) indicate that the rate was greater than that in
period 1 whilst open squares (blue open circles in the web version) indicate the converse.
K.A. Andrews et al. / Neurobiology of Aging 39 (2016) 99e107 103
conﬁdence intervals: 153 (86e332) and 157 (87e324) over 0e18 m
and 18e36 m, respectively. However, for the other measures of
atrophy, there were considerable, albeit nonsigniﬁcant (as assessed
by consideration of conﬁdence intervals on ratios of sample size
estimates), reductions in numbers needed between the 2 time
periods: for whole brain atrophy rates reductions were from 211
(70e1148) to 105 (43e304) per arm, whilst for rates of left and right
hippocampal atrophy reductions were from 701 (206e61,824) to
164 (77e426) per arm and from 490 (182e3645) to 261 (114e875)
per arm, respectively.
4. Discussion
In this study, we conﬁrm an independent relationship between
baseline amyloid load and rates of neurodegeneration over
36 months, provide evidence that atrophy rates are also inﬂuenced
by the rate of amyloid accumulation in the ﬁrst 18-month period,
and show that these relationships are largely driven by individuals
who are initially amyloid positive. We provide evidence that, as
predicted by current hypotheses, asymptomatic amyloid-positive
individuals, but not amyloid-negative individuals, show accelera-
tion in rates of hippocampal atrophy. Finally, we demonstrate that
sample sizes for clinical trials in asymptomatic amyloidosis based
on rates of brain atrophy are dependent not only on the “length” of
the trial, but particularly in the case of hippocampal atrophy, on the
“timing” of a putative trial, with some evidence that smaller
numbers are required closer to predicted disease onset. Impor-
tantly, this has implications for clinical trial design in prodromal
disease, demonstrating that whilst it may be reasonable to assume
linear change over longer periods, trials over shorter periods or
adopting run-in designs cannot assume a consistent linear rate of
decline.
The relationship between amyloid deposition and rates of atrophy
has been investigated in a number of studies.Whereas some failed to
determine a relationship between amyloid load and global cortical
gray matter atrophy in asymptomatic individuals (Storandt et al.,
2012), our ﬁnding that baseline amyloid burdendindependent of
age, APOE status, or cognitiondindependently inﬂuences rates of
brain atrophy, hippocampal atrophy, and ventricular expansion in
asymptomatic elderly individuals conﬁrms and extends our previous
ﬁndings over shorter intervals (Andrews et al., 2013; Schott et al.,
2010b) and those of others (Chételat et al., 2012; Scheinin et al.,
2009). Taken together with the ﬁnding that atrophy rates are asso-
ciated not only with baseline amyloid load but also with rate of
amyloid accumulation, conﬁrming ﬁndings from a previous report
(Villemagne et al., 2013), this provides strong evidence not only for a
close link between the presence of signiﬁcant brain amyloid and
downstream neurodegeneration but also suggests that there is also a
dynamic elementwith “on-going” amyloid accumulation inﬂuencing
rate of neurodegeneration. This in turn suggests that strategies to
prevent further amyloid accumulation may impact on rate of neu-
rodegeneration, andperhaps theemergenceof symptoms, even if the
neurodegenerative process has already been initiated.
Our ﬁnding of acceleration of rate of hippocampal atrophy in the
amyloid-positive group, with trends for acceleration in measures of
whole brain change, is consistent with current models of AD
pathogenesis, which predict both that increased rates of atrophy
within medial temporal structures occurs before increase in more
global atrophy measures (Jack et al., 2010; Schott et al., 2003;
Whitwell et al., 2007; Young et al., 2014), but also that the rate of
change is sigmoidaldthat is, associated with an initial period of
acceleration (Caroli and Frisoni, 2010; Jack et al., 2013; Schuff et al.,
2012). This suggests that acceleration of atrophy starts both some
time after the build-up of signiﬁcant amyloid load, and at least
18 months before symptom onset, in keeping with the current
model of biomarker progression (Jack et al., 2013). Several longi-
tudinal studies have demonstrated acceleration of brain atrophy in
symptomatic familial Alzheimer’s disease (Chan et al., 2003; Ridha
et al., 2006), and sporadic MCI or Alzheimer’s disease (Jack et al.,
2008b; Leung et al., 2013; Schuff et al., 2009). Carlson and col-
leagues reported that rates of ventricular enlargement in healthy
controls increased more than 2 years before the emergence of
clinical cognitive impairment (Carlson et al., 2008). Sabuncu and
colleagues reported acceleration of cortical thinning and hippo-
campal loss in the early stages of the disease, measured over 3 time
points in the course of 1 year (Sabuncu et al., 2011), but this ac-
celeration, as in a number of the aforementioned studies, was
calculated across the cohort relative to MMSE score, rather than on
the basis of individual subject scans. Our results are, to the best of
our knowledge, the ﬁrst demonstration of within-subject, pre-
symptomatic acceleration of hippocampal atrophy rates in
amyloid-positive individuals. Moreover, by using amethodology for
calculating rates of change that has been, and continues to be, used
in clinical trials, our data can be used to explore the effect that this
acceleration might have on sample sizes for similar trials.
Although increased rates of atrophy in relation to baseline
amyloid load, and acceleration of hippocampal atrophy, were seen
across the group as a whole, these results were predominantly
driven by those individuals with asymptomatic amyloidosis. Mean
rates of whole brain, hippocampal atrophy, and ventricular
expansion were very similar in both 18-month periods in the
amyloid-negative group. By contrast, in the amyloid-positive group,
hippocampal atrophy was approximately 2-3 fold higher in the
second 18 months compared to the ﬁrst, with whole brain atrophy
approximately doubling, and rate of ventricular expansion also
increasing. For clinical trials, particularly for rates of hippocampal
change, the increase inmean rate of change in the second 18-month
time period results in somewhat reduced sample size estimates
during this period. It should be noted that whilst the sample sizes
presented here are relatively small, they are based on absolute re-
ductions of 25%. Assuming that drug treatment would at most
reduce rates of atrophy to those of the amyloid-negative group this
equates to a treatment effect of 48% for whole brain, 53% for ven-
tricles, and 38% for hippocampi.
Independent of the absolute sample size estimates which are
based on relatively small numbers, the demonstration of accelera-
tion in rates of hippocampal atrophy and its effects on sample sizes
has more general implications for the design of disease-modifying
trials using rates of atrophy as outcome measures in asymptom-
atic amyloidosis. As sample sizes are critically dependent not only
on the absolute extent of change but also on the standard deviation
of the observed change, it is not surprising that smaller sample sizes
are required for trials over 36 compared to 18 months. The
demonstration of acceleration of atrophy between 2 successive 18-
month intervals suggests that over shorter periods it may be not
only the length of the trial, but the “proximity” to symptom onset
that will inﬂuence required sample sizes. It follows that run-in trial
designs, which depend on extrapolation of rate of change from an
initial period off-treatment to that on the study drug, may not be
able to assume the same rate of linear decline between both periods
at least in the presymptomatic phase; and there are likely to be
similar caveats for cross-over trials at this stage of the disease.
This study has a number of limitations. The study period extends
only over 36 months and 3 time points precluding a more ﬁne-
grained assessment of the dynamics of biomarker change. The
number of individuals in the study is relatively small, meaning that
considerable caution is required when interpreting the sample size
estimates for clinical trials, which require further replication in
larger groups, are best considered indicative, and are based on the
premise that treatment will attenuate rates of atrophy.We note that
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the rates of hippocampal atrophy presented here over the ﬁrst
18 months are somewhat lower than we have previous reported
from a slightly larger sample of this cohort (n ¼ 66) (Andrews et al.,
2013). Excluded individuals had either not attended for a third MRI
or had not had a second amyloid PET scan. A higher proportion of
missing individuals were amyloid positive (9/22) than amyloid
negative (4/44). Although none of the amyloid-negative missing
individuals had left the study at the third time point, more than half
(5/9) of the amyloid-positive group had. Of those missing, 3 with
particularly high rates of atrophy included one who had converted
to a diagnosis of “other dementia”, another who had converted to
MCI, whereas the third had not been available for assessment at the
third time point. These results demonstrate the suggestion that
individuals dropping out of clinical trials, even at the asymptomatic
stage, should not be assumed to be missing completely at random
(Schott and Bartlett, 2012).
5. Conclusions
These results clearly distinguish between levels and dynamics of
rates in “healthy” normal aging and in asymptomatic amyloidosis,
being consistent both with the initial upswing in atrophy rates
described by the sigmoidal curves proposed in Jack et al. (2010) and
investigated in further longitudinal studies (Caroli and Frisoni,
2010; Jack et al., 2013; Sabuncu et al., 2011; Schuff et al., 2012)
andwith a sequence of events whereby amyloid accumulation leads
to acceleration of downstream neurodegeneration and cognitive
decline, consistent with the proposedmodel of disease progression.
Using methodologies currently in use in clinical trials, we demon-
strate that rate of accumulation of amyloid as well as absolute level
of deposited ﬁbrillar amyloid inﬂuence rates of atrophy, suggesting
that strategies to slow amyloid accumulation as opposed to pro-
moting clearance may also be beneﬁcial. The demonstration that
hippocampal atrophy rates accelerate before symptom onset in
amyloid-positive individuals suggests that clinical trial design in
asymptomatic amyloidosis should not assume linear rates of
biomarker progression.
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